OR WAIT null SECS
November 02, 2017
Recent acquisitions are creating CDMOs with scale that rivals global bio/pharma.
October 13, 2017
Predicted areas of growth include flow chemistry, fermentation, repatriation of overseas funds, oncology, and API/product integration, but the rate of change is unclear.
October 02, 2017
Mergers and acquisitions are positive for the CDMO industry, but there is a downside.
September 02, 2017
Innovation speeds discovery, drives down costs, and improves productivity.
August 02, 2017
Despite some progress, the industry is still in a wait-and-see mode regarding the administration, Congress, and FDA.
August 01, 2017
CMOs must embrace flexibility in their technology decisions and business arrangements.
July 02, 2017
As pharma models changed during the past 40 years, contract manufacturing capacity and services evolved to meet demand.
May 02, 2017
CMOs may be gaining as strategic partners to large bio/pharma companies, but they have a much harder path to navigate.
November 02, 2016
CMO executives are focusing on M&A activity, new business models, and fundraising limits.
September 02, 2016
The strategies of a innovation-driven CMO may be different than a capacity-driven CMO.